|
[posting]61709302[/posting]Ein weiteres attraktives Produkt von CORV ist Treyvent das von Steadymed entwickelt worden ist welche ich damals auch empfohlen und später für über $200 Million von UTHR übernommen wurde . https://www.stockwatch.com/News/Item.aspx?bid=Z-C%3aCORV-280… Correvio Pharma Corp. holds commercial rights to Trevyent for the international markets of Europe and the Middle East and expects to file regulatory submissions for Trevyent in Europe in mid-2020. About pulmonary arterial hypertension Pulmonary arterial hypertension is a type of high blood pressure that occurs in the right side of the heart and in the arteries that supply blood to the lungs. PAH worsens over time and is life-threatening because the pressure in a patient's pulmonary arteries rises to dangerously high levels, putting a strain on the heart. There is no cure for PAH, but several medications are available to treat symptoms, such as the market-leading prostacyclin PAH therapy, Remodulin (treprostinil) Injection, which is produced by United Therapeutics Corp. United Therapeutics reported Remodulin revenues of $599-million in 2018. |
|
| aus der Diskussion: | CORV (Mkap $95 M) FDA Entscheidung in Dezember /ADCOM eventuell in November |
| Autor (Datum des Eintrages): | Biohero (17.10.19 19:39:15) |
| Beitrag: | 3 von 212 (ID:61713076) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |